Share on facebook Share on Twitter Share on Google Plus Share This

Nephrology

Publications

A total of 93 print publications and 20 epublications were authored and/or co-authored by Division members in 2017. An asterisk beside a name indicates a current trainee as an author.

2017 Print Publications

1. Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension: focus on the brain. Curr Opin Nephrol Hypertens 2017;26:106-113. PubMed PMID: 27906749.

2. Adrogué HJ, Madias NE. In reply to ‘Sodium-chloride difference as a simple parameter for acid-base assessment.’ Am J Kidney Dis 2017;69:708. Epub 2017 Mar 9. PubMed PMID: 28285872.

3. Adrogué HJ, Madias NE. Nonosmotic Na+ storage and the Edelman equation. Kidney Int 2017;92:514. PubMed PMID: 28709601.

4. Alam A, Perrone RD. Autosomal dominant PKD in patients with PKD2 mutations – a benign disorder? Am J Kidney Dis 2017;70:456-457. PubMed PMID: 28941485.

5. Aymé S, Bockenhauer D, Day S, Devuyst O, Guay-Woodford LM, Ingelfiner JR, Klein JB, Knoers NVAM, Perrone RD, Roberts J, Schaefer F, Torres VE, Cheung M, Wheeler DC, Winkelmayer WC;Conference Participants. Common elements in rare kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017;92:796-808. PubMed PMID: 28938953.

6. Bansal N, Katz R, Robinson-Cohen C, Odden MC, Dalrymple L, Shlipak MG, Sarnak MJ, Siscovick DS, Zelnick L, Psaty BM, Kestenbaum B, Correa A, Afkarian M, Young B, de Boer IH. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies. JAMA Cardiol 2017;2:314-318. PubMed PMID: 28002548.

7. Bansal VK, Herzog CA, Sarnak MJ, Choi MJ, Mehta R, Jaar BG, Rocco MV, Kramer H. Oral anticoagulants to prevent stroke in nonvalvular atrial fibrillation in patients with CKD stage 5D: an NKF-KDOQI controversies report. Am J Kidney Dis 2017;70:859-868. Epub 2017 Sep 21. PubMed PMID: 28941763.

8. Bansal VK, Zelnich LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, Katz R, Kestenbaum B, Matthew J, Robinson-Cohen C, Sarnak MJ, Shlipak MG, Sotoodehnia N, Young B, Heckbert SR. eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol 2017;12:1386-1398. Epub 2017 Aug 10. PubMed PMID: 28798221.

9. Bar-Nur D, Jaber BL. Mineralocorticoid receptor blockade for prevention of acute kidney injury: an elusive target. Am J Kidney Dis 2017;69:166-168. PubMed PMID: 28115063.

10. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P. Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J;SPRINT Research Group. Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med 2017;377:733-744.

11. Carrero JJ, Grams ME, Sang Y, Ärnlöv J, Gasparini A, Matsushita K, Qureshi AR, Evans M, Barany P, Lindholm B, Ballew SH, Levey AS, Gansevoort RT, Elinder CG, Coresh J. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int 2017;91:244-251. Epub 2016 Dec 4. PubMed PMID: 27927597.

12. Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, Leliveld AM, Ouyang J, Perrone RD, Torres VE, Gansevoort RT;TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcome) 3:4 Trial Investigators. Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 Trial. Am J Kidney Dis 2017;69:210-219. Epub 2016 Nov 14. PubMed PMID: 27856088.

13.  Charytan DM, Solomon SD, Ivanovich P, Remuzzin G, Cooper ME, McGill JB, Parving JJ, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA. ESRD after heart failure, myocardial infarction, or stroke in type 2 diabetic patients with CKD. Am J Kidney Dis 2017;70:522-531. Epub 2017 Jun 7. PubMed PMID: 28599901.

14.  Chen DP, Davis BR, Simpson LM, Cushman WC, Cutler JA, Dobre M, Ford CE, Louis GT, Muntner P, Oparil S, Piller LB, Pressel SL, Sarnak MJ, Whelton PK, Wright JT, Rahman M. Association between chronic kidney disease and cancer mortality: a report from the ALLHAT. Clinic Nephrol 2017;87:11-20. PubMed PMID: 27900942.

15.  Dad T*, Garimella PS, Strom JA. Quiz: an unusual case of metabolic alkalosis in a patient with CKD. Am J Kidney Dis 2017;69:A13-A16. PubMed PMID: 28007194.

16.  Dad T*, Weiner DE. Does an aspirin a day keep the doctor away? Am J Kidney Dis 2017;69:337-340. Epub 2016 Nov 23. PubMed PMID: 27889297.

17.  Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2017;28:1592-1602. Epub 2016 Dec 5. PubMed PMID: 27920153.

18.  Drew DA, Katz R, Kritchevsky S, Ix J, Shlipak M, Gutiérrez OM, Newman A, Hoofnagle A, Fried L, Semba RD, Sarnak M. Association between soluble klotho and change in kidney function: the Health Aging and Body Composition Study. J Am Soc Nephrol 2017;28:1859-1866. Epub 2017 Jan 19. PubMed PMID: 28104822.

19.  Drew DA, Koo BB, Bhadelia R, Weiner DE, Duncan S, la Garza MM, Gupta A, Tighiouart H, Scott T, Sarnak MJ. White matter damage in maintenance in hemodialysis patients: a diffusion tensor imaging study. BMC Nephrol 2017;18:213. PubMed PMID: 28676035.

20. Drew DA, Weiner DE, Tighiouart H, Duncan S, Gupta A, Scott T, Sarnak MJ. Cognitive decline and its risk factors in prevalent hemodialysis patients. Am J Kidney Dis 2017;69:780-787. Epub 2017 Jan 26. PubMed PMID: 28131531.

21. Foster MC, Levey AS, Inker LA, Shafi T, Fan L, Gudnason V, Katz R, Mitchell GF, Okparavero A, Palsson R, Post WS, Shlipak MG. Non-GFR determinants of low-molecular-weight serum protein filtration markers in the elderly: AGES-Kidney and MESA-Kidney. Am J Kidney Dis 2017;70:406-414. Epub 2017 May 24. PubMed PMID: 28549536.

22. Foster MC, Weiner DE, Bostom AG, Carpenter MA, Inker LA, Jarolim P, Joseph AA, Kusek JW, Pesavento T, Pfeffer MA, Rao M, Solomon SD, Levey AS. Filtration markers, cardiovascular disease, mortality, and kidney outcomes in stable kidney transplant recipients: the FAVORIT Trial. Am J Transplant 2017;17:2390-2399. Epub 2017 Mar 30. PubMed PMID: 28257169.

23. Gabbay E, Meyer KB. Amazing and fantastic infection control: the case of dialyzer reuse. Am J Kidney Dis 2017;69:717-719. PubMed PMID: 28532633.

24.  Garimella PS, Bartz TM, Is JH, Chonchol M, Shlipak MG, Devarajan P, Bennett MR, Sarnak MJ. Urinary uromodulim and risk of urinary tract infections: the Cardiovascular Health Study. Am J Kidney Dis 2017;69:744-751. Epub 2016 Oct 28. PubMed PMID: 28029393.

25.  Garimella PS, Jaber BL, Tighiouart H, Liangos O, Bennett MR, Devarajan P, El-Achkar TM, Sarnak MJ. Association of preoperative urinary uromodulin with AKI after cardiac surgery. Clin J Am Soc Nephrol 2017;12:10-18. Epub 2016 Oct 26. PubMed PMID: 27797887.

26.  Garimella PS, Katz R, Ix JH, Fried LF, Kritchevsky SB, Devarajan P, Bennett MR, Parikh CR, Shlipak MG, Harris TB, Gutiérrez OM, Sarnak MJ. Association of urinary uromodulin with kidney function decline and mortality: the health ABC study. Clin Nephrol 2017;87:278-286. PubMed PMID: 28332475.

27.  Garimella PS, Sarnak MJ. Uromodulin in kidney and health disease. Curr Opin Nephrol Hypertens 2017;26:136-142. PubMed PMID: 278985524.

28.  Ginsberg C, Katz R, de Boer IH, Kestenbaum BR, Chonchol M, Shlipak MG, Sarnak MJ, Hoofnable AN, Rifkin DE, Garimella PS, Ix JH. The 24.25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The Cardiovascular Health Study. Bone 2017;107:124-130. Epub 2017 Nov 16. PubMed PMID: 29155243.

29.  Grams ME, Tin A, Rebholz CM, Shafi T, Köttgen A, Perrone RD, Sarnak MJ, Inker LA, Levey AS, Coresh J. Metabolomic alterations associated with cause of CKD. Clin J Am Soc Nephrol 2017;12:1787-1794. Epub 2017 Sep 28. PubMed PMID: 28971980.

30.  Grams ME, Yang W, Rebholz CM, Wang X, Porter AC, Inker LA, Horwitz E, Sondheimer JH, Hamm LL, He J, Weir MR, Jaar BG, Shafi T, Appel LJ, Hsu CY;CRIC Study Investigators. Risks of adverse events in advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2017;70:337-346. Epub 2017 Mar 30. PubMed PMID: 28366517.

31.  Grantham JJ, Chapman AB, Blais J, Czerwiec FS, Devuyst O, Gansevoort RT, Higashihara E, Krasa H, Zhou W, Ouyang J, Perrone RD, Torres VE;TEMPO 3:4 Investigators. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transpl 2017;32:969-975. PubMed PMID: 27190355.

32.  Gupta A, Mahnken JD, Johnson DK, Thomas TS, Subramanian D, Polshak T, Gani I, John Chen G, Burns JM, Sarnak MJ. Prevalence and correlates of cognitive impairment in kidney transplant recipients. BMC Nephrol 2017;18:158. PubMed PMID: 28499360.

33.  Gupta N, Jaber BL. Hospital-Based Management of Kidney Stones. In: McKean S, Ross J, Dressler D, Brotman D, Ginsberg J, eds. Principles and Practice of Hospital Medicine. McGraw-Hill Medical, pp 1993-1999, 2017

34.  Halpin M, Kozyreva O, Bijol V, Jaber BL. Plasmapheresis for treatment of immune complex-mediated glomerulonephritis in infective endocarditis: a case report and literature review. Clin Nephrol Case Stud 2017;5:26-31. PubMed PMID: 29043144.

35.  Hayek SS, Koh KH, Grams ME, Wei C, Ko Y, Li J, Samelko B, Lee H, Dande RR, Lee JW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Barborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J. A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease. Nat Med 2017;23:945-953. PubMed PMID: 28650456.

36.  Huang N, Foster MC, Mitchell GF, Andresdottir MB, Eiriksdottir G, Gudmundsdottir H, Harris TB, Launer LJ, Palsson R, Gudnason V, Levey AS, Inker LA. Aortic stiffness and change in glomerular filtration rate and albuminuria in older people. Nephrol Dial Transpl 2017;32:677-684. PubMed PMID: 27190377.

37.  Hughes-Austin JM, Rifkin DE, Beben T, Katz R, Sarnak MJ, Deo R, Hoofnagle AN, Homma S, Siscovick DS, Sotoodehnia N, Psaty BM, de Boer IH, Kestenbaum B, Shlipak MG, Ix JH. The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals. Clin J Am Soc Nephrol 2017;12:245-252. Epub 2017 Jan 31. PubMed PMID: 28143865.

38.  Inker LA, Levey AS.  Assessment of kidney function in acute and chronic settings.  In Gilbert SJ, Weiner DE, Bomback AS, Perazella MA, Tonelli M (eds).  Primer on Kidney Diseases 7th Edition.  Elsevier, Philadelphia, PA 2018; pp 26-32.

39.  Inker LA, Levey AS.  Staging and management of chronic kidney disease.  In Gilbert SJ, Weiner DE, Bomback AS, Perazella MA, Tonelli M (eds).  Primer on Kidney Diseases 7th Edition.  Elsevier, Philadelphia, PA 2018; pp 476-483.

40. Inker LA, Coresh J, San Y, Hsu CY, Foster MC, Eckfeldt JH, Karger AB, Nelson RG, Liu X, Sarnak M, Appel LJ, Grams M, Xie D, Kimmel PL, Feldman H, Ramachandran V, Jaber BL. Clinical nephrology. Curr Opin Nephrol Hypertens 2017;26:105. PubMed PMID: 27922850.

41. Levey AS;CKD Biomarkers Consortium. Filtration markers as predictors of ESRD and mortality: individual participant date meta-analysis. Clin J Am Soc Nephrol 2017;12:69-78. Epub 2016 Nov 10. PubMed PMID: 28062677.

42. Inker LA, Huang N, Levey AS. Strategies for assessing GFR and albuminuria in the living kidney donor evaluation. Curr Transplant Rep 2017;4:13-23. Epub 2017 Jan 29. PubMed PMID: 28944160.

43.  Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Flessner MF, Torres VE;HALT Investigators. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transpl 2017;32:1857-1865. PubMed PMID: 27484667.

44. Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, Bansal V, Rosas SE, Nigwekar S, Yee J, Kramer H. KDOQI US commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2017;70:737-751. Epub 2017 Sep 21. PubMed PMID: 28941764.

45. Ix JH, Katz R, Bansal N, Foster M, Weiner DE, Tracy R, Jotwani V, Hughes-Austin J, McKay D, Gabbai F, Hsu CY, Bostom A, Levey AS, Shlipak MG. Urine fibrosis markers and risk of allograft failure in kidney transplant recipients: a case-cohort ancillary study of the FAVORIT Trial. Am J Kidney Dis 2017;69:410-419. Epub 2016 Dec 23. PubMed PMID: 28024930.

46.  Karaboyas A, Zee J, Brunelli SM, Usvyat LA, Weiner DE, Maddux FW, Nissenson AR, Jadoul M, Locatelli F, Winkelmayer WC, Port FK, Robinson BM, Tentori F. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysate Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2017;69:266-277. Epub 2016 Nov 17. PubMed PMID: 27866964.

47.  Kraut JA, Madias NE. Adverse effects of the metabokic acidosis of chronic kidney disease. Adv Chronic Kidney Dis 2017;24:289-297. PubMed PMID: 29031355.

48.  Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese VM, Jamerson K, Gassman JJ, Smogorzewski M, Hsu CY. Acute declines in renal function during intensive BP lowering: implications for future ESRD risk. J Am Soc Nephrol 2017;28:2794-2801. Epub 2017 May 4. PubMed PMID: 28473636.

49.  Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Gutiérrez OM, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT Jr., Wyatt C, Hsu CY. BP control and long-term risk of ESRD and mortality. J Am Soc Nephrol 2017;28:671-677. Epub 2016 Aug 11. PubMed PMID: 27516235.

50.   Ladin K, Lin N, Hahn E, Zhang G, Koch-Weser S, Weiner DE.  Engagement in decision-making and patient satisfaction: a qualitative study for older patients’ perceptions of dialysis initiation and modality decisions. Nephrol Dial Nephrol 2017;32:1394-1401. PubMed PMID: 27576590.

51.  Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX. KDIGO Clinical Practice Guidelines on the Evaluation and Care of Living Kidney Donors. Transplantation 2017;101:S1-S109. PubMed PMID: 28742762.

52.  Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX. Summary of Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on the Evaluation and Care of Living Kidney Donors. Transplantation 2017;101:1873-1792. PubMed PMID: 28737659.

53.  Leonberg-Yoo AK, Sarnak MJ. Don’t pass the salt: evidence to support avoidance of high salt intake in CKD. Am J Kidney Dis 2017;69:175-178. Epub 2016 Oct 24. PubMed PMID: 27789126.

54.  Leonberg-Yoo AK, Tighiouart H, Levey AS, Beck GJ, Sarnak MJ. Urine potassium excretion, kidney failure, and mortality in CKD. Am J Kidney Dis 2017;69:341-349. Epub 2016 May 24. PubMed PMID: 27233381.

55.  Levey AS, Eckfeldt JH. Estimating glomerular filtration rate using serum creatinine. Clin Chem 2017;63:1161-1162. Epub 2017 Apr 5. PubMed PMID: 28381407.

56.  Levey AS, Inker LA. GFR evaluation in living kidney donor candidates. J Am Soc Nephrol 2017;28:1062-1071. Epub 2017 Mar 15. PubMed PMID: 28298325.

57.  Levey AS, Inker LA. Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther 2017;102:405-419. Epub 2017 Jun 5. PubMed PMID: 28474735.

58.  Levey AS, James MT. Acute kidney injury. Ann Int Med 2017;16:ITC66-ITC80. PubMed PMID: 29114754.

59.  Levey AS, Levin A. A rebuttal to “The CKD classification system in the precision medicine era.” Clin J Am Soc Nephrol 2017;12:1711-1713. Epub 2017 Aug 7. PubMed PMID: 28784654.

60.  Levey AS, Tighiouart H, Simon AL, Inker LA. Comparing newer GFR estimating equations using creatinine and cystatin C to the CKD-EPI equations in adults. Am J Kidney Dis 2017;70:587-589. Epub 2017 May 26. PubMed PMID: 28552371.

61.  Levey AS, Tighiouart H, Simon AL, Inker LA. In reply to ‘Newer GFR estimating equations require validation in different populations.’ Am J Kidney Dis 2017;70:586-587. Epub 2017 Aug 11. PubMed PMID: 28807402.

62.  Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M, Kasiske B, Köttgen A, Kretzler M, Levey AS, Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N, Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle KR, Wheeler DC, Eckardt KU;ISN Global Kidney Health Summit participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 2017;390:1888-1917. Epub 2017 Apr 20. PubMed PMID: 28434650.

63.  Levey AS, Tighiouart H, Simon AL, Inker LA. Comparing newer GFR estimating equations using creatinine and cystatin C to the CKD-EPI equations in adults. Am J Kidney Dis 2017;70:587-598. Epub 2017 May 26. PubMed PMID: 28552371. Correspondence: In reply to “Newer GFR estimating equations require validation in different populations.’ Am J Kidney Dis 2017;70:586-587. Epubl 2017 Aug 11. PubMed PMID: 28807402.

64.  Maltais JB, Meyer KB, Foster MC. Comparison of techniques for culture of dialysis water and fluid. Hemodial Int 2017;21:197-205. Epub 2016 Sep 5. PubMed PMID: 27594052.

65.  McCausland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol 2017;46:488-497. PubMed PMID: 29241199.

66.  McGill RL, Ruthazer R, Lacson E Jr, Meyer KB, Miskulin DC, Weiner DE. Vascular imaging of hemodialysis vascular access planning. Hemodial Int 2017;21:490-497. Epub 2016 Nov 20. PubMed PMID: 27868336.

67.  McGill RL, Ruthazer R, Meyer KB, Miskulin DC, Weiner DE. Peripherally inserted central catheters and hemodialysis outcomes. Clin J Am Soc Nephrol 2017;11:1434-1440. Epub 2016 Jun 23. PubMed PMID: 27340280.

68.  McGill RL, Weiner DE. Dialysate composition for hemodialysis: changes and changing risks. Semin Dial 2017;30:112-120. Epub 2017 Jan 8. PubMed PMID: 28066927.

69.  Merhi B, Shireman T, Carpenter MA, Kusek JW, Jacques P, Pfeffer M, Rao M, Foster MC, Kim SJ, Pesavento TE, Smith SR, Kew CE, House AA, Gonh R, Weiner DE, Levey AS, Ix JH, Bostom A. Serum phosphorus and risk of cardiovascular disease, all-cause mortality, or graft failure in kidney transplant recipients: an ancillary study of the FAVORIT Trial Cohort. Am J Kidney Dis 2017;70:377-385. Epub 2017 Jun 2. PubMed PMID: 28579423.

70.  Michels WM, Jaar BG, Ephraim PL, Liu Y, Miskulin DC, Tangri N, Crews DC, Scialla JJ, Shafi T, Sozio SM, Bandeen-Roche K, Cook CJ, Meyer KB, Boulware LE;DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Intravenous iron administration strategies and anemia management in hemodialysis patients. Nephrol Dial Transplant 2017;32:173-181. PubMed PMID: 27604984.

71.  Miskulin DC, Gul A. Infection monitoring in dialysis units: a plea for “cleaner” data. Clin J Am Soc Nephrol 2017;12:1038-1039. Epub 2017 Jun 29. PubMed PMID: 28663226.

72.  Miskulin DC, Weiner DE. Blood pressure management in hemodialysis patients: what we know and what questions remain. Semin Dial 2017;30:203-212. Epub 2017 Mar 6. PubMed PMID: 28264150.

73.  Neijenhuis MK, Kievit W, Perrone RD, Sloan JA, Erwin P, Murad MH, Gever TJG, Hogan MC, Drenth JPH. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression. BMC Nephrol 2017;18:169. PubMed PMID: 28545401.

74.  Perl J, Dember LM, Bargman JM, Browne T, Charytan DM, Flythe JE, Jickson LJ, Hung AM, Jadoul M, Lee TC, Meyer KB, Moradi H, Shafi T, Teitelbaum I, Wong LP, Chan CT;American Society of Nephrology Dialysis Advisory Group. The use of a multidimensional measure of dialysis adequacy-moving beyond small solute kinetics. Clin J Am Soc Nephrol 2017;12:839-847. Epub 2017 Mar 17. PubMed PMID: 28314806.

75.  Perrone RD, Moukassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. A drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2017;2:451-460.

76.  Perrone RD, Moukassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2017;2:442-450. PubMed PMID: 29142971.

77.  Rebholz CM, Inker LA, Chen Y, Liang M, Foster MC, Eckfeldt JH, Kimmel PL, Vasan RS, Feldman HI, Sarnak MJ, Hsu CY, Levey AS, Coresh J;Chronic Kidney Disease Biomarkers Consortium. Risk of ESRD and mortality associated with change in filtration markers. Am J Kidney Dis 2017;70:551-560. Epub 2017 Jun 23. PubMed PMID: 28648303.

78.  Scott TM, Rogers G, Weiner DE, Livingston K, Selhub J, Jacques PF, Rosenberg IH, Troen AM. B-vitamin therapy for kidney transplant recipients lowers homocysteine and impoves selective cognitive outcomes in the randomized FAVORIT ancillary cognitive trial. J Prev Alzheimers Dis 2017;4:174-184. PubMed PMID: 29182708.

79.  Shafi T, Sozio SM, Luly J, Bandeen-Roche KJ, St. Peter WL, Ephraim PL, McDermott A, Herzog CA, Crews DC, Scialla JJ, Tangri N, Miskulin DC, Michels WM, Jaar BG, Zager PG, Meyer KB, Wu AW, Boulware LE;DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: evidence from a cohort study to inform hypertension treatment practices. Medicine (Baltimore) 2017;96:e5924. PubMed PMID: 28151871.

80.  Sharma S, Sarnak MJ. Epidemiology: The global burden of reduced GFR: ESRD, CVD and mortality. Nat Rev Nephrol 2017;13:447-448. PubMed PMID: 28626221.

81.  Shea MK, Booth SL, Weiner DE, Brinkley TE, Kanaya AM, Murphy RA, Simonsick EM, Wassel CL, Vermeer C, Kritchevsky SB;Health ABC Study. Circulating vitamin K is inversely associated with incident cardiovascular disease risk among those treated for hypertension in the Health, Aging, and Body Composition Study (Health ABC). J Nutr 2017;147:888-895. Epub 2017 Mar 29. PubMed PMID: 28356433.

82.  Smitson CC, Scherzer R, Shlipak MG, Psaty BM, Newman AB, Sarnak MJ, Odden MC, Peralta CA. Association of blood pressure trajectory with mortality, incident cardiovascular disease, and heart failure in the Cardiovascular Heart Study. Am J Hypertens 2017;30:588-593. PubMed PMID: 28338937.

83.  Tangri N, Inker LA, Hiebert B, Wong J, Naimark D, Kent D, Levey AS. A dynamic predictive model for progression of CKD. Am J Kidney Dis 2017;69:514-520. Epub 2016 Sep 29. PubMed PMID: 27693260.

84.  Thomas B, Matsushita K, Abate KH, Al-Aly Z, Asayam K, Atkins R, Badawi A, Ballew SH, Banerjee A, Barregárd L, Barrett-Connor E, Basu S, Bello AK, Bensenor I, Bergstrom J, Bikbov B, Blosser C, Brenner H, Carrero JJ, Chadban S, Cirillo M, Cortinovis M, Courville K, Dandona L, Dandona R, Estep K, Fernandes J, Fischer F, Fox C, Gansevoort RT, Gona PN, Gutierrez OM, Hamidi S, Hanson SW, Himmelfarb J, Jassal SK, Jee SH, Jha V, Jimenez-Corona A, Jonas JB, Kengne AP, Khader Y, Khang YH, Kim YJ, Klein B, Klein R, Kokubo Y, Kolte D, Lee K, Levey AS, Li Y, Lotufo P, El Razek HMA, Mendoza W, Metoki H, Mok Y, Muraki I, Muntner PM, Noda H, Ohkubo T, Ortiz A, Perico N, Polkinghorne K, Al-Radaddi R, Remuzzi G, Roth G, Rothenbacker D, Satoh M, Saum KU, Sawhney M, Schöttker B, Shankar A, Shlipak M, Silva DAS, Toyoshima H, Ukwaja K, Umesawa M, Voliset SE, Warnock DG, Werdecker A, Yamagishi K, Yano Y, Yonemoto N, Zaki MES, Naghavi M, Forouzanfar MH, Murray CJL, Coresh J, Vos T;Global Burden of Disease 2013 GFR Collaborators;CKD Prognosis Consortium;Global Burden of Disease Genitourinary Expert Group. Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol 2017;28:2167-2179. Epub 2017 Apr 13. PubMed PMID: 28408440.

85.  Tong A, Gill J, Budde K, Marson L, Reese PP, Rosenbloom D, Rostaing L, Wong G, Josephson MA, Pruett TL, Warrens AN, Craig JC, Sautenet B, Evangelidis N, Ralph AF, Hanson CS, Shen JI, Howard K, Meyer K, Perrone RD, Weiner DE, Fung S, Ma MKM, Rose C, Ryan J, Chen LX, Howell M, Larkins N, Kim S, Thangaraju S, Ju A, Chapman JR;SONG-Tx Investigators. Toward establishing core outcome domains for trials ki kidney transplantation: report of the Standardized Outcomes in Nephrology-Kidney Transplantation Consensus Workshops. Transplantation 2017;101:1887-1896. PubMed PMID: 28737661.

86.  Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 2017;91:493-500. Epub 2016 Dec 16. PubMed PMID: 27993381.

87.  Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD;TEMPO 4:4 Trial Investigators. Erratum: Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transpl 2017;32:1262. PubMed PMID: 28444221.

88. Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O;REPRISE Trian Investigators. Rationale and design of a clinical trial investigating tolvaptan safety and efficacy in autosomal dominant polycystic kidney disease. Am J Nephrol 2017;45:257-266. Epub 2017 Feb 7. PubMed PMID: 28166521.

89. Upadhyay A, Jaber BL. Reuse and biocompatibility of hemodialysis membranes: clinically relevant? Semin Dial 2017;30:121-124. Epub 2017 Jan 8. PubMed PMID: 28066932.

90. Upadhyay A, Susantitaphong P, Jaber BL. Ultrapure versus standard dialysate: a cost-benefit analysis. Semin Dial 2017;30:398-402. Epub 2017 Jun 13. PubMed PMID: 28608933.

91.  Weiner DE, Gaussoin SA, Nord J, Auchus AP, Chelune GJ, Chonchol M, Coker L, Haley WE, Killeen AA, Kimmel PL, Lerner AJ, Oparil S, Saklayan MG, Slinin YM, Wright CB, Williamson JD, Kurella Tamura M;SPRINT Study Research Group. Cognitive function and kidney disease: baseline data from the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis 2017;70:357-367. Epub 2017 Jun 9. PubMed PMID: 28606731.

92.  Weiner DE, Sarnak MJ: Cardiac Function and Cardiac Disease in Chronic Kidney Disease. In Gilbert S, Weiner D et al (ed): Primer on Kidney Diseases (ed 7).  Philadelphia, PA, Elsevier, 2017, pp 535-543.

93. Wongrakpanich S, Susantitaphong P, Isaranuwatchai S, Chenbhanich J, Eiam-Ong S, Jaber BL. Dialysis therapy and conservative management of advanced chronic kidney disease in the elderly. Nephron 2017;137:178-189. Epub 2017 May 25. PubMed PMID: 28538218.

2017 Epublications

1. Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, Pfeffer MA, Rossing P, Walsh M Wanner C, Wheeler DC, Winkelmayer WC, McMurray JJV;KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants. Challenges in concluding clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017;92:297-305. PubMed PMID: 28709600.

2. Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc 2017 Jul 19;pii:e005428;doi:10.1161.JAHA.116.005428. PubMed PMID: 28724651.

3. Beumer JH, Inker LA, Levey AS. Improving carboplatin dosing based on estimated GFR. Am J Kidney Dis 2017 Dec 4;pii:S0272-6386(17)310117-X;doi:10.1053/j.ajkd.2017.10.005. PubMed PMID: 29217306.

4. Björk J, Brugg A, Gudnason V, Indridason OS, Levey AS, Palsson R, Nyman U. Comparison of glomerular filtration rate estimating equation derived from creatinine and cystatin C: validation of the Age, Gen/Enviroment Susceptibility-Reykjavik elderly cohort. Neph Dial Transpl;2017 Oct 5;doi:10.1093/ndt/gfx272. PubMed PMID: 29040701.

5. Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW. ADPKD progression in patients with no apparent family history and no mutation detected by Sanger sequencing. Am J Kidney Dis 2017 Dec 1;pii:S0272-6386(17)30969-1;doi:10.1053/j.ajkd.2017.09.008. PubMed PMID: 29203126.

6. Brosnahan G, Abebe KZ, Rahbari-Oskoui FF, Patterson CD, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE, The Halt PKD Investigators. Effect of statin therapy on progression of autosomal dominant polycystic kidney disease: a secondary analysis of the HALT PKD trials. Curr Hypertens Rev 2017 Apr 27;doi:10.2174/1573402113666170427142815. PubMed PMID: 28460625.

7. Chen W, Newman AB, Fried LF, Rifkin DE, Shlipak MG, Sarnak MJ, Katz R, Madero M, Raphael KL, Bushinsky DA, Ix JH. Relationship of acid-base status with arterial stiffness in community-living elders: the Health ABC Study. Nephrol Dial Transplant 2017 Nov 21;doi:10.1093/ndt/gfx292. PubMed PMID: 29177410.

8. Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephol Dial Transpl 2017 Jul 19;doi:10.1093/ndt/gfx188. PubMed PMID: 28992127.

9. Gupta A, Thomas TS, Klein JA, Montgomery RN, Mahnken JD, Johnson DK, Drew DA, Sarnak MJ, Burns JM. Discrepancies between perceived and measured cognition in kidney transplant patients recipients: implications for clinical management. Nephron 2017 Oct 20;doi:10.1159/000481182. PubMed PMID: 29049997.

10. Inker LA, Levey AS, Tighiouart H, Shafi T, Eckfeldt JH, Johnson C, Okparavero A, Post WS, Coresh J, Shlipak MG. Performance of glomerular filtration rate estimating equations in a community-based sample of Blacks and Whitles: the Multiethnic Study of Atherosclerosis. Nephrol Dial Transpl 2017 May 13;doi:10.1093/ndt/gfx042. PubMed PMID: 28505377.

11. Ladin K, Buttafarro K, Hahn E, Koch-Weser S, Weiner DE. “End of life care? I’m not going to worry about that yet.” Health literacy gaps and end-of-life planning among elderly dialysis patients. Gerontologist 2017 Mar 10;doi:10.1093/geront/gnw267. PubMed PMID: 28329829.

12. Lang J, Katz R, IX JH, Gutierrez OM, Peralta CA, Parikh CR, Satterfield S, Petrovic S, Devarajan P, Bennett M, Fried LF, Cummings SR, Sarnak MJ, Shlipak MG. Association of serum albumin levels with kidney function decline and incident chronic kidney disease in elders. Nephrol Dial Transplant 2017 Aug 23;doi:10.1093/ndt/gfx229. PubMed PMID: 28992097.

13.Kraut JA, Madias NE. Retarding progression of chronic kidney disease: use of modalities that counter acid retention. Curr Opin Nephrol Hypertens 2017 Nov 14;doi:10.1097/MNH.0000000000000386. PubMed PMID: 29140821.

14. Miskulin DC, Gassman J, Schraeder R, Gul A, Jhamb M, Ploth DW, Negrea L, Kwong RY, Levey AS, Singh AK, Harford A, Paine S, Kendrick C, Rahman M, Zager P. BP in dialysis: results of a pilot study. J Am Soc Nephrol 2017 Dec 6;pii:ASN.2017020135;doi:10.1681/ASN.2017020135. PubMed PMID: 29212839.

15. Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and obesity are predictors in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2017 Nov 8;pii:ASN.2017070819;doi:10.1681/ASN.201070819. PubMed PMID: 2918087.

16. Oberdhan D, Cole JC, Krasa HB, Cheng R, Czerwiec FS, Chapman AB, Perrone RD. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument. Am J Kidney Dis 2017 Nov 14;pii:S0272-6386(17)30951-4;doi:10.1053/j.ajkd.2017.08.020. PubMed PMID: 29150246.

17. Riefkohl A, Ramirez-Rubio O, Laws RL, McClean MD, Weiner DE, Kaufman JS, Galloway RL, Shadomy SV, Guerra M, Amador JJ, Sánchez JM, López-Pilarte D, Parikh CR, Brooks DR. Leptospira seropositivity as a risk factor for Mesoamerican Nephropathy. Int J Occup Environ Health 2017 Feb 17;doi:10.1080/10773525.2016.1275462. PubMed PMID: 28209095.

18. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O;REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017 Nov 4;doi:10.1056/NEJMoz1710030. PubMed PMID: 29105594.

19. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD;TEMPO 4:4 Trial Investigators. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transpl 2017 Mar 31;doi:10.1093/ndt/gfx043. PubMed PMID: 28379536.

20. Tsipotis E, Price LL, Jaber BL, Madias NE. Hospital-associated hypernatremia spectrum and clinical outcomes in an unselected cohort. Am J Med 2017 Aug 20;pii:S0002-9343(17)30841-0;doi:10.1016/j.amjmed.2017.08.011. PubMed PMID: 2880033.